Title: Longterm Impact of COVID-19 in Hospitalized and Ambulatory Jamaican Children

Co-authors and Institutions:

- Samantha Ann-Patrice Mosha Miller, BA, BSc, MBBS, Faculty of Medical Sciences, Department of Child and Adolescent Health, University of the West Indies, Mona, Kingston 7, Jamaica. Email: samantha.mosha@gmail.com; Ph: 876 582 5355, ORCID 0009-0008-6052-4259
- Mark Daniel Hicar, MD, PhD, Jacobs School of Medicine and Biomedical Sciences and University at Buffalo, Department of Pediatrics (Infectious Diseases), Buffalo, New York, USA; markhica@buffalo.edu; Ph: 716 323 0150; ORCID 0000-0002-1768-5419
- Crista-Lee Shahine Berry, MBBS, DM Peds, RCPSC-SEAP(Resp), Faculty of Medical Sciences, Dept of Child and Adolescent Health (Pediatric Respirology), University of the West Indies, Mona, Kingston 7, Jamaica. Email: berryrespirology2@gmail.com ORCID 0000-0002-9149-889X
- Kathryn B. Anderson, MD, PhD, CTrop Med, Center for Global Health and Translational Sciences, Dept of Immunology and Microbiology, Upstate Medical University, New York, USA. Email: AndeKath@upstate.edu; Ph:315 464 5815 ORCID 0000-0002-5725-2351
- John F. Lindo, PhD. Faculty of Medical Sciences, Department of Microbiology, University of the West Indies, Mona, Kingston 7, Jamaica. Email. John.Lindo@uwi.edu; Ph: 876 371 6292 ORCID 0000-0002-4781-4998
- Gene D. Morse, PharmD, Center for Integrated Global Biomedical Sciences, School of Pharmacy and Pharmaceutical Sciences, University of Buffalo, New York, USA; Email: emorse@buffalo.edu ORCID 0000-0001-6758-0941

- Celia Dana Claire Christie, MBBS, DM Peds, MPH. Faculty of Medical Sciences, Department of Child and Adolescent Health (Pediatric Infectious Diseases), University of the West Indies, Mona, Kingston 7, Jamaica. Email: Celia.ChristieSamuels@uwimona.edu.jm;, or celiachristie02@gmail.com; ORCID 0000-0002-8981-3934; Ph: 876 927 1446 (O), or 876 399 2773 (Cell).

Corresponding Co-author:

Celia DC Christie, MBBS, DM Peds, MPH. Professor Emerita of Pediatrics (Infectious Diseases), Department of Child and Adolescent Health (Pediatric Infectious Diseases), University of the West Indies, Mona., Kingston 7, Jamaica, Email: Celia.ChristieSamuels@uwimona.edu.jm;, or celiachristie02@gmail.com; Ph: 876 927 1446 (O), or 876 399 2773 (Cell).

Key words:

SARS-CoV-2; Long COVID-19; Post COVID condition; Children and adolescents; Jamaica.

Cover Title and Running Heading: Long COVID-19 in Jamaican Children

Disclosure of Funding for this work:

Dr. Mosha Miller is a post-doctoral trainee in the UWI Global Infectious Diseases (GID) Research Training Program (grant # 2D43TW01091906) funded by the Fogarty International Center of the National Institutes of Health, USA. Drs. Lindo, Morse and Anderson receive partial support from the GID (grant # 2D43TW01091906) and this collaborative research initiative was organized through the SUNY-UWI Health Research Consortium, USA.

FOOTNOTES:

This manuscript is an abbreviation of the full Doctoral Thesis, which was submitted by Dr. Samantha Mosha Miller in support of her 4-year Doctorate in Child and Adolescent Health (Pediatrics) Degree from the University of the West Indies, Mona Campus (Thesis Supervisor – Dr Celia DC Christie). It was also the subject of a platform presentation by Dr. Samantha Mosha Miller at the Global Virus Network Conference at the University of the West Indies' Faculty of Medical Sciences in Jamaica early in 2025.

Special thanks to our **independent contractors** who were paid specifically to work on this project, Ms. Paulette Palmer, Senior Research Nurse, in the Department of Child and Adolescent Health at UWI Mona and Dr. Zachary Ramsay, Research Fellow at the Caribbean Institute of Health Research, UWI and our excellent statistician.

ABSTRACT **Word count – 249**

Background: Within the Caribbean, COVID-19 and its sequelae in the pediatric population have been understudied. We sought to characterize Long COVID-19 in this population. Predictors and outcomes of Long COVID-19 were evaluated in hospitalized and ambulatory patients aged <16 years receiving treatment during 2021-2023 at the University Hospital of the West Indies, Jamaica.

Methods: This retrospective observational cohort study, approved by the University's Ethics Committee, extracted medical records data from ill SARS-CoV-2 positive patients and then surveyed this cohort for symptoms of Long COVID-19. Poisson regression models accounted for varying follow-up times after acute COVID-19 and generated univariate and multivariable models for predictors of Long COVID-19.

Results: Forty-seven percent of the 74 survey responders met the WHO's 2023 pediatric criteria for Long COVID-19. Common symptoms included cough, chest tightness, fatigue, congestion, ageusia, anosmia, anorexia, and insomnia. Acute illness symptoms associated with Long COVID-19 included fatigue, vomiting, diarrhea, anosmia, abdominal pain, confusion, brain fog, persistent chest tightness, cough, nasal congestion, ageusia, anosmia, insomnia, and chest pain (IRR=1.61-2.56; p=0.000-0.034). Between those with and without Long COVID-19, there were no significant differences in demographics, comorbidities, SARS-CoV-2 variant, site of care, functional impairment and quality of life. Acute illness univariate Long COVID-19 predictors were vomiting, abdominal pain, ageusia, fatigue, confusion, brain fog, and multisystem inflammatory syndrome of children (MIS-C) ($p<0.05$;

IRR>1.0). Multivariable composite predictors were MIS-C, vomiting, and ageusia (Pseudo R^2:11.9%; $p<0.001$).

Conclusion: This 47% prevalence of Long COVID-19 in pediatric patients implies potential negative outcomes in productivity, academic performance, and comorbidity development.

INTRODUCTION: **Word Count – 2,901**

When Coronavirus disease 2019 (COVID-19) emerged, children had a milder course than adults.[1] Initially, adults' COVID-19 symptoms persisted longer than expected, and later reports suggested that children were also at risk of developing post-COVID conditions.[1-8] COVID-19 outcomes in Caribbean children at the University Hospital of the West Indies (UHWI), Jamaica, demonstrated the disparity between the usually mild clinical course of children and more severe post-COVID sequelae.[9] The initial striking post-COVID condition included those who developed the severe complication of "Multi-system Inflammatory Syndrome in Children" (MIS-C), characterized by hyperinflammation involving $\geq$2 organ systems occurring 2-6 weeks after acute SARS-CoV-2 infection.[3-5]

Early in the pandemic, in addition to MIS-C, "Long COVID-19" was also identified in children.[6,8] Longer-term persistent manifestations resulted from tissue damage, viral persistence, infection chronicity, immune system dysregulation, autoimmunity, and chronic inflammation.[10-15] The major risk factor for Long COVID-19 was severe COVID-19 infection, associated with extremes of age, ethnicity, prematurity, comorbidities, an elevated C-reactive protein and hypersensitivity.[16]

In February 2023, the WHO published a "globally relevant standardized case definition" for Long COVID-19 in children and adolescents: "Post COVID-19 condition in children and adolescents occurs in individuals with a history of confirmed, or probable SARS-CoV-2 infection, when experiencing symptoms lasting at least 2 months which initially occurred within 3 months of acute COVID-19."[17] Symptoms generally affect every day functioning.[17] They may be new-onset following the initial recovery from an acute COVID-19 episode, persist, fluctuate, or relapse over time.[17] Additional diagnoses do not exclude a post COVID-

19 condition.[17] The WHO commissioned a panel of 27 experts to update their meta-analysis (review of 60 studies inclusive of 328,875 participants) from University College London which informed the Delphi process.[17] The 60 studies comprising cohort (38) and cross-sectional (16) studies, and also case series (6), were gleaned from a review of 4,416 studies.[17]

In 2024, the Researching COVID to enhance recovery (RECOVER) pediatric study published a protocol for a multicenter observational cohort study across the United States.[18] Participants with MIS-C had poorer outcomes, and symptom clusters were used to create Long COVID-19 predictors.[19]

Within the Caribbean, COVID-19 and its sequelae in the pediatric population have been understudied. The effects of COVID-19 on the physical and social well-being of Jamaican families were explored in only one study of children and adults during the pandemic.[20] The Long COVID-19 prevalence was 39% in the only Caribbean study which involved adults and children, from Bonaire.[21]

This study aims to evaluate the risk factors and long-term impact of COVID-19 in children and adolescents aged <16 years with a history of confirmed, or probable COVID-19 who were hospitalized, or received ambulatory care from January 2021 through December 2023 (3 years) at the University Hospital of the West Indies (UHWI), in Kingston, Jamaica, a middle-developing, Caribbean, island-nation. For analysis, we defined the cutoff of circulation of the Delta SARS-CoV-2 “Variant of Concern” as all of 2021 and Omicron going forward from 2022 through 2023, according to Jamaica’s national surveillance criteria.

METHODS

This retrospective observational cohort study was conducted at UHWI. We used UHWI's laboratory data management system to locate all positive SARS-CoV-2 PCR and serology tests for patients aged < 16 years. The laboratory listings were cross-referenced with emergency room registers, hospital inpatient registers, and pediatric infectious disease consultations.

Patients were excluded if: they were ≥ 16 years; they were "swab-and-go" records (had SARS-CoV-2 testing related to contact tracing but were never registered as patients); their medical records could not be located (the hospital operated a hybrid physical and electronic medical records system at the time); their contact information was outdated; or multiple attempts at making contact were unsuccessful; or after providing consent, if further attempts at making contact were unsuccessful.

We used a modified WHO case report form as a data-extraction instrument to evaluate and retrospectively collect data from inpatient and outpatient hospital charts (**Appendix**). We applied the WHO's February 2023 clinical criteria[17] for identifying children and adolescents with Long COVID-19 to patients aged <16 years who had laboratory-confirmed SARS-CoV-2 infection from January 2021 to December 2023. We then conducted oral telephone interviews using a modified International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) COVID-19 long-term follow-up survey (**Appendix**). These data were all used to determine those who met the WHO's criteria for acute Long COVID-19 in children and adolescents and to assess their outcomes.

Ethical approval was obtained from the University's Mona Campus Research Ethics Committee.

All main variables had ≤ 5% missingness, considered negligible by statistical guidelines. [22] Categorical variables were described using frequencies and cross-tabulations; numerical variables used means, standard deviations, medians, and interquartile ranges. A robust Poisson regression model was used with the Huber/White/sandwich estimator to account for variable follow-up times (median 24 months, IQR 18-36 months), and robust standard errors corrected for over-dispersion. The models produced incidence rate ratios based on clinical and demographic factors. Both univariate and multivariable models were generated, with the latter assessed using Pseudo R^2, Akaike Information Criterion (AIC), and Bayesian Information Criterion (BIC). Pearson's chi-squared, Wilcoxon rank-sum, and Kruskal-Wallis tests were used to evaluate significant differences in the distribution of symptoms among participants with and without Long COVID, as well as main outcomes as compared across clinical and demographic factors. Statistical significance was set at $p<0.05$, and all analyses were performed using the STATA 16.

RESULTS

From January 2021 to December 2023, the UHWI laboratory system had 704 positive SARS-CoV-2 records for patients aged < 16 years. SARS-CoV-2 positivity was identified using rapid antigen tests, PCR and serological assays. The emergency room register documented 180 positive tests, the in-patient register accounted for 181, and the pediatric infectious disease consultation reports had 69 patients with positive results. When we accounted for the overlap of patients among these groups and "swab-and-go" patients, we found 229 unique

symptomatic patients. Of these, 139 were inpatients, and 90 were outpatients. We verified the contact information of 212 patients and located 177 medical records. We contacted 138 participants via phone calls, WhatsApp messages, and/or emails. We consented 82 patients, and eight did not go on to participate. Therefore, 74 participants were interviewed. Participants were interviewed 24 months (median, IQR 18-30 months) after acute SARS-CoV-2 infection. All were of Afro-Caribbean descent, with 54.1% (n=40) males and 45.9% (n=34) females with a mean age of 9.1 ± 5.6 years (**Table 1**).

Acute COVID-19 infections were documented in 2021 (n=30;40.5%), 2022 (n=34;45.9%), and 2023 (10;13.4%); thus, the temporal classification suggested that the Delta variant accounted for 40.5% and Omicron accounted for 59.5% (**Table 1**). Most patients had laboratory-confirmed SARS-CoV-2 infection (n=69;94.5%), with 4.1% (n=3) and 1.4% (n=1) reported as physician-confirmed and self-diagnosed, respectively. Of those who tested positive for SARS-CoV-2, 63.8% (n=44) had positive PCR results, 29.0% (n=20) had positive antigen test results, and 30.4% (n=21) were diagnosed serologically, with some overlap among the three groups.

In Jamaica, SARS-CoV-2/COVID-19 vaccines were only offered to the pediatric population aged ≥ 12 years. Only six children (8.1%) in our cohort were vaccinated: one received the AstraZeneca vaccine, and 5 received the Pfizer vaccine. When we accounted for age restrictions, 22.2% of the 27 patients ≥12 years received a vaccine.

Our main outcomes were Long COVID-19, MIS-C, and hospitalization (**Table 1**). Almost half of our patients met WHO's criteria for Long COVID-19 (n=35;47.3%). Twenty-four (24;32.4%) participants developed MIS-C after initial SARS-CoV-2 infection. Another

32.4% (n=24) of patients were hospitalized for acute COVID-19. Only one patient (4.8%) received Intensive Care, whereas three (12.5%) were readmitted. Furthermore, of the 24 participants who were hospitalized for acute COVID-19, 20% developed Long COVID-19. Chronic illnesses included sickle cell disease, asthma, obesity, neurological disorders, and food allergies (**Table 1**). There were no significant associations between premorbid illnesses and Long COVID-19. Except for two chronic illnesses, which were too few to be meaningful. Only two participants had pre-existing renal disease and met the Long COVID-19 criteria. The two participants with leukemia were asymptomatic of their acute infection and did not develop Long COVID-19.

The most frequently reported acute COVID-19 symptoms were fever (55.4%), cough (43.2%), shortness of breath (21.6%), fatigue (17.6%), rhinorrhea (16.2%), vomiting (14.9%), headache (10.8%), and loss of taste (9.5%). Moreover, several symptoms demonstrated statistically significant associations with Long COVID-19 based on the univariate robust Poisson regression models (**Figure**). Regarding fatigue, 25.7% of those who went on to develop Long COVID-19 experienced this symptom, while only 10.3% of those who did not develop Long COVID-19 experienced this symptom (IRR 1.84; 95% CI 1.26-2.68; p = 0.002). Significant differences were also noted with vomiting (25.7% vs 5.1%; IRR 2.18; 95% CI 1.39-3.41; p = 0.001), diarrhea (14.3% vs 2.6%; IRR 2.03; 95% CI 1.12-3.69; p = 0.020), loss of smell (11.4% vs 0.0%; IRR 1.65; 95% CI 1.24-2.18; p = 0.001), abdominal pain (5.7% vs 0.0%; IRR 1.78; 95% CI 1.21-2.59; p = 0.003), confusion (5.7% vs 0.0%; IRR 2.56; 95% CI 1.34-4.90; p = 0.004), brain fog (5.7% vs 0.0%; IRR 1.78; 95% CI 1.38-2.29; p = 0.000) (**Figure**).

The most common persistent symptoms were cough (85.1%), chest tightness (16.2%), fatigue (14.9%), congestion (14.9%), ageusia (13.5%), anosmia (10.8%), appetite loss (9.5%), and insomnia (9.5%). All these symptoms showed a statistically significant association with the development of Long COVID-19 and chest pain (6.8%). Chest tightness was experienced by 34.3% of those who met the criteria for Long COVID-19 vs. 0.0% of those who did not (IRR 2.81; 95% CI 1.96-4.02; p=0.000). Significant results for the remaining symptoms were: cough 28.6% vs 2.6% (IRR 0.37; 95% CI 0.25-0.54; p=0.000); nasal congestion 25.7% vs 5.1% (IRR 2.34; 95% CI 1.60-3.42; p=0.000), fatigue 25.7% vs 5.1% (IRR 1.77; 95% CI 1.13-2.79; p=0.013); loss of taste 22.9% vs 5.1% (IRR 1.61; 95% CI 1.04-2.51; p=0.034); insomnia 20.0% vs 0.0% (IRR 2.15; 95% CI 1.53-3.04; p=0.000); loss of smell 87.5% vs 12.5% (IRR 1.85; 95% CI 1.27-2.71; p=0.001); and chest pain 14.3% vs 0.0% (IRR 2.56; 95% CI 1.89-3.47; p=0.000) (**Figure**).

We explored functional impairment and quality of life in relation to Long COVID-19. Functional impairment was assessed based on mobility, self-care, usual activities such as attending school, pain or discomfort, and negative emotions before and after the COVID-19 infection. Most participants reported having no problems in any domain, regardless of whether they developed Long COVID-19 (**Table 2**). Quality of life was also assessed through changes in activities, such as eating and sleeping, neuropsychiatric symptoms (e.g., fatigue, memory, and concentration), social relationships, and emotional well-being before and after COVID-19. No statistically significant associations were observed between these domains.

We investigated the relationship between elevated inflammatory markers on presentation to the hospital and the development of Long COVID-19 (**Table 3**). C-reactive protein, erythrocyte sedimentation rate, D-dimer, lactate dehydrogenase, and absolute neutrophil

counts were all higher in the Long COVID-19 group (**Table 3**). However, these differences were not statistically significant in the univariate robust Poisson regression model. Surprisingly, ferritin levels were significantly elevated in the non-Long COVID-19 group (**Table 3**).

Our hospitalized MIS-C cohort received several interventions, including anticoagulants, anti-inflammatory drugs, intravenous immunoglobulin (IVIgG), aspirin, antivirals, antibiotics, and corticosteroids (**Table 3**). There was no significant association between individual interventions and the development of Long COVID-19 based on univariate robust Poisson regression models.

Univariate Poisson regression models revealed single predictors of the development of Long COVID-19 (**Table 4**). Significant associations were found in patients with MIS-C as well as several acute COVID-19 symptoms, including confusion, fatigue, vomiting, abdominal pain, anosmia, ageusia, and brain fog. Furthermore, multivariate analysis demonstrated that MIS-C, vomiting, and ageusia together formed a composite predictive model for Long COVID-19 (Pseudo R^2:11.9%; likelihood ratio test: $p<0.001$) (**Table 4**).

DISCUSSION

To our knowledge, this is the first study to employ the WHO Pediatric Long COVID-19 case definition. It is also the first to address Long COVID-19 in Jamaica and Caribbean pediatric populations. Moreover, our cohort consisted entirely of children of Afro-Caribbean descent from a developing country, a population that is underrepresented in the literature.

Almost half (47.3%) of the 74 participants met the WHO 2023 criteria for pediatric Long COVID-19. This synchronizes with the 20.0%-47.8% in the global literature.[23-26]

The most common acute COVID-19 symptoms were fever, cough, shortness of breath, fatigue, and rhinorrhea. However, fatigue and vomiting were significant risk factors for Long COVID-19. Less common risk factors were other gastrointestinal symptoms, such as abdominal pain, diarrhea, and anosmia, which are pathognomonic for COVID-19, and neuropsychiatric symptoms, such as brain fog and confusion. SARS-CoV-2 persists in gastrointestinal tissue for up to four months after acute infection.[15, 27-29] Microstructural changes in the cerebrum may also be related to anosmia and memory loss.[0] These could account for the persistence of these symptoms and their association with Long COVID-19.

Although a myriad of persistent symptoms has been reported, not every symptom meets the threshold for Long COVID-19 diagnosis. These persistent symptoms include cough, chest tightness, fatigue, congestion, ageusia, anosmia, anorexia, and insomnia.[24,26,31,32] These symptoms and chest pain were significantly associated with the development of Long COVID-19. The RECOVER study found similar predictors, including age group, citing gastrointestinal, neuropsychiatric, and pain-related complaints as predictors in school-aged children, while adolescents who experienced ageusia, anosmia, fatigue, and pain during their acute COVID-19 infection were more likely to develop Long COVID-19.[19]

There were no statistically significant associations between Long COVID-19 and demographics, circulating SARS-CoV-2 variants, or hospitalization status. None of the most reported chronic illnesses was significantly associated with Long COVID-19. However, renal disease and leukemia were two of the least reported comorbidities and both showed

significant associations, with renal disease associated with a higher incidence risk of Long COVID-19 and leukemia with a lower incidence risk. Although there were too few cases of these illnesses to make meaningful conclusions, it is possible that renal disease was associated with an immunocompromised state that predisposed them to contracting COVID-19 yet permitted the inflammation that led to Long COVID-19. Patients with leukemia were also more susceptible to contracting COVID-19; however, their immunosuppressive therapies could have precluded a robust inflammatory response and be protective against developing Long COVID-19.

Investigation of inflammatory marker levels revealed that during acute COVID-19 infection, ferritin levels were significantly higher in those who did not develop Long COVID-19. Ferritin has been highlighted as a predictor of severe COVID-19.[33,34] Patients with more severe COVID-19 would have been hospitalized and received immunosuppressive interventions that lessened their likelihood of chronic inflammation. Thus, patients with higher ferritin levels initially would have been less likely to have ongoing inflammation and to develop Long COVID-19.

There was no statistically significant impairment of function or quality of life in children with Long COVID-19, although this has been reported.[35,36] Most reported no limitations before and after the COVID-19 infection. Perceptions of impairment may have been affected by sedentary lifestyles and home schooling during the pandemic compared with the lifting of lockdown and subsequent increased activity at the time of the interview.

Individual predictors of Long COVID-19 were acute COVID-19 symptoms, including vomiting, abdominal pain, ageusia, fatigue, confusion, brain fog, and MIS-C. Multivariable

analysis showed that a composite model comprising MIS-C, vomiting, and ageusia was a significant predictor. The RECOVER study similarly noted the predictive value of neuropsychiatric symptoms, although they probed a wider variety of responses within that system.[19] This would imply that Long COVID-19 may increase the mental health burden on not only children and adolescents, but also the healthcare system if it is not addressed forthwith.

LIMITATIONS:

This study had a relatively small sample size and was susceptible to recall bias, as in other similar studies. To mitigate against this, the interview data were cross-referenced with patients' medical records. This study may have a significant nonresponse bias with roughly one-third of eligible subjects completing surveys. The higher rate of MIS-C supports both a nonresponse bias and a lack of capture of circulating pediatric COVID-19 cases. To assess symptoms and compare them to presenting data, our study included children who sought medical care, whether hospitalized or ambulatory. We hypothesized that the proportion of patients who developed Long COVID-19 would be higher in our hospitalized cases; however, only 20% of hospitalized participants with acute COVID-19 developed Long COVID-19. Our ambulatory population received only supportive care, whereas our hospitalized patients received immunoglobulin, anti-inflammatory, and antimicrobial therapies, which likely reduced chronic inflammation of Long COVID-19. Specific SARS-CoV-2 strain sequencing data were unavailable, so circulating Delta and Omicron variants were estimated from community data. We lacked community controls; however we assumed community spread by the time the study was implemented.

CONCLUSION:

Half of our participants met the WHO criteria for Pediatric Long COVID-19. Acute COVID-19 symptoms that were risk factors for Long COVID-19 included fatigue, confusion, brain fog, anosmia, vomiting, diarrhea, and abdominal pain. Persistent symptoms associated with the development of Long COVID-19 were fatigue, insomnia, anosmia, ageusia, cough, chest pain, chest tightness, and nasal congestion. Single variable predictors of Long COVID-19 were acute vomiting, abdominal pain, ageusia, fatigue, confusion, brain fog, and MIS-C. Multivariate analysis demonstrated that MIS-C with vomiting and ageusia was a composite predictor of Long COVID-19.

Long COVID-19 may reduce the quality-of-life metrics. Aggressive management of acute COVID-19 may reduce the prevalence of Long COVID-19. This requires increased resources for robust SARS-CoV-2 testing and pharmacotherapy, which may be inaccessible in similar resource-constrained settings. Healthcare providers should be vigilant in identifying Long COVID-19 in children. Earlier interventions, with referrals for developmental and academic adjunctive services, may reduce the long-term impact on the healthcare and education systems. This is important in regions with insufficient access to adequate medical technology, which may result in late diagnoses and poor health outcomes.

FUNDING:

Dr. Samantha Mosha Miller is a post-doctoral trainee in the UWI Global Infectious Diseases (GID) Research Training Program (grant # 2D43TW01091906), funded by the Fogarty International Center of the **National Institutes of Health**, USA. Drs. Lindo, Morse, and Anderson received partial support from the GID (grant # 2D43TW01091906), and this collaborative research initiative was organized through the SUNY-UWI Health Research Consortium, USA.

ACKNOWLEDGEMENTS:

We thank the participants, co-investigators, and the Department of Child and Adolescent Health of the University of the West Indies (UWI) at Mona, Jamaica, and the contributing Departments of the University Hospital of the West Indies (*viz*: Child and Adolescent Health, Hematology, Microbiology, Chemistry, Pharmacy, Radiology). We also thank the parents, guardians, children, and adolescents who participated in this study.

Special thanks to our **independent contractors** who were paid specifically to work on this project, Ms. Paulette Palmer, Senior Research Nurse, in the Department of Child and Adolescent at UWI Mona and Dr. Zachary Ramsay, Research Fellow at the Caribbean Institute of Health Research, and our excellent statistician.

This manuscript is an abbreviation of the Doctoral Thesis, which was submitted by Dr. Samantha Mosha Miller in support of her 4-year Doctorate in Child and Adolescent Health (Pediatrics) Degree from the University of the West Indies, Mona Campus (Thesis Supervisor – Dr Celia DC Christie). It was also summarized for a platform presentation by Dr. Samantha Mosha Miller at the Global Virus Network Conference at the University of the West Indies' Faculty of Medical Sciences in Jamaica.

ETHICAL APPROVAL:

Ethical approval for the study was obtained from the Mona Campus Research Ethics Committee (MCREC), of the University of the West Indies, in accordance with the Data Protection Act of Jamaica. Parents/guardians provided written informed consent to participate in the study, which required a modified ISARIC survey and review of medical records to extract data using modified WHO case report forms. Written permission was received to utilize the ISARIC survey for this study. In accordance with the Data Protection Act of Jamaica, the team member who sought informed consent from participants was different from the team member who administered the survey.

CONFLICT OF INTEREST:

None to declare.

REFERENCES

1. Cui X, Zhao Z, Zhang T, Guo W, Guo W, Zheng J, et al. A systematic review and meta□analysis of children with coronavirus disease 2019 (COVID□19). Journal of Medical Virology. 2020;93(2):1057–69.

2. Gomes C. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19). Brazilian Journal of Implantology and health sciences. 2020;2(3).

3. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. The Lancet Child & Adolescent Health. 2020;395(10237):1607–8.

4. Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, et al. An outbreak of severe kawasaki-like disease at the Italian epicentre of the SARS-COV-2 epidemic: An observational cohort study. The Lancet. 2020;395(10239):1771–8.

5. Jiang L, Tang K, Irfan O, Li X, Zhang E, Bhutta Z. Epidemiology, Clinical Features, and Outcomes of Multisystem Inflammatory Syndrome in Children (MIS-C) and Adolescents—a Live Systematic Review and Meta-analysis. Curr Pediatr Rep. 2022 June;10(2):19–30.

6. Ludvigsson J. Case report and systematic review suggest that children may experience similar long□term effects to adults after clinical covid□19. Acta Paediatrica. 2020;110(3):914–21.

7. Fainardi V, Meoli A, Chiopris G, Motta M, Skenderaj K, Grandinetti R, et al. Long COVID in Children and Adolescents. Life. 2022 Feb 14;12(2):285.

8. Lopez-Leon S, Wegman-Ostrosky T, Ayuzo Del Valle NC, Perelman C, Sepulveda R, Rebolledo PA, et al. Long-COVID in children and adolescents: a systematic review and meta-analyses. Sci Rep. 2022 June 23;12(1):9950.

9. Berry CL, Melbourne-Chambers R, Harrison A, Anzinger J, Gordon-Johnson KA, Deyde V, et al. Hospitalized children with SARS-COV-2 infection and MIS-C in Jamaica: A dive into the first 15 months of the novel pandemic. Frontiers in Pediatrics [Internet]. 2022;10. Available from: https://www.frontiersin.org/articles/10.3389/fped.2022.904788/full

10. Yong S. Long Covid or post-covid-19 syndrome: Putative pathophysiology, risk factors, and treatments. Infectious Diseases. 2021;53(10):737–54.

11. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr;181(2):271-280.e8.

12. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid—mechanisms, risk factors, and management. BMJ. 2021 July 26;n1648.

13. Sante GD, Buonsenso D, De Rose C, Valentini P, Ria F, Sanguinetti M, et al. Immune profile of children with post-acute sequelae of SARS-CoV-2 infection (Long Covid)

[Internet]. Pediatrics; 2021 May [cited 2024 Jan 22]. Available from: http://medrxiv.org/lookup/doi/10.1101/2021.05.07.21256539

14. Karlsson A, Humbert M, Buggert M. The known unknowns of T cell immunity to covid-19. Science Immunology [Internet]. 2020;5(53). Available from: https://www.science.org/doi/full/10.1126/sciimmunol.abe8063

15. Hu F, Chen F, Ou Z, Fan Q, Tan X, Wang Y. A compromised specific humoral immune response against the SARS-CoV-2 receptor-binding domain is related to viral persistence and periodic shedding in the gastrointestinal tract. Cellular & Molecular Immunology. 2020;17(11):1119–25.

16. Osmanov I, Spiridonova E, Bobkova P, Gamirova A, Shikhaleva A, Andreeva M, et al. Risk factors for post-covid-19 condition in previously hospitalised children using the ISARIC Global Follow-up protocol: A prospective cohort study. European Respiratory Journal [Internet]. 2021;59(2). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576804/

17. www.who.int [Internet]. 2023 [cited 2023 Jan 1]. A clinical case definition for post COVID-19 condition in children and adolescents by expert consensus, 16 February 2023. Available from: https://iris.who.int/bitstream/handle/10665/366126/WHO-2019-nCoV-Post-COVID-19-condition-CA-Clinical-case-definition-2023.1-eng.pdf

18. Gross RS, Thaweethai T, Rosenzweig EB, Chan J, Chibnik LB, Cicek MS, et al. Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and design. Plos one. 2024;19(5):e0285635.

19. Gross RS, Thaweethai T, Kleinman LC, Snowden JN, Rosenzweig EB, Milner JD, et al. Characterizing Long COVID in Children and Adolescents. JAMA. 2024 Oct 8;332(14):1174.

20. Samms-Vaughan M, Pellington S, Reynolds-Salmon R. Impact of COVID-19 on Young Children and Families in Jamaica. Journal of Research in Childhood Education. 2024;38(sup1):S24–38.

21. Berry DS, Dalhuisen T, Marchena G, Tiemessen I, Geubbels E, Jaspers L. The prevalence of post COVID-19 condition (PCC) and a simple risk scoring tool for PCC screening on Bonaire, Caribbean Netherlands: a retrospective cohort study [Internet]. Public and Global Health; 2023 [cited 2025 May 30]. Available from: http://medrxiv.org/lookup/doi/10.1101/2023.06.20.23291646

22. Jakobsen JC, Gluud C, Wetterslev J, Winkel P. When and how should multiple imputation be used for handling missing data in randomised clinical trials – a practical guide with flowcharts. BMC Med Res Methodol. 2017 Dec;17(1):162.

23. Asadi-Pooya AA, Nemati H, Shahisavandi M, Akbari A, Emami A, Lotfi M, et al. Long COVID in children and adolescents. World J Pediatr. 2021 Oct;17(5):495–9.

24. Buonsenso D, Munblit D, Pazukhina E, Ricchiuto A, Sinatti D, Zona M, et al. Post-COVID Condition in Adults and Children Living in the Same Household in Italy: A Prospective Cohort Study Using the ISARIC Global Follow-Up Protocol. Front Pediatr. 2022 Apr 21;10:834875.

25. Bloise S, Isoldi S, Marcellino A, De Luca E, Dilillo A, Mallardo S, et al. Clinical picture and long-term symptoms of SARS-CoV-2 infection in an Italian pediatric population. Ital J Pediatr. 2022 Dec;48(1):79.

26. Kikkenborg Berg S, Dam Nielsen S, Nygaard U, Bundgaard H, Palm P, Rotvig C, et al. Long COVID symptoms in SARS-CoV-2-positive adolescents and matched controls (LongCOVIDKidsDK): a national, cross-sectional study. The Lancet Child & Adolescent Health. 2022 Apr;6(4):240–8.

27. Park S kyung, Lee CW, Park DI, Woo HY, Cheong H, Shin H, et al. Detection of SARS-COV-2 in fecal samples from patients with asymptomatic and mild COVID-19 in Korea. Clinical Gastroenterology and Hepatology [Internet]. 2021;19(7). Available from: https://www.sciencedirect.com/science/article/pii/S1542356520307771

28. Wu Y, Guo C, Tang L, Hong Z, Zhou J, Dong X, et al. Prolonged presence of SARS-COV-2 viral RNA in faecal samples. The Lancet Gastroenterology & Hepatology. 2020;5(5):434–5.

29. Gaebler C, Wang Z, Lorenzi J, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 591(7851):639–44.

30. Lu Y, Li X, Geng D, Mei N, Wu PY, Huang CC, et al. Cerebral micro-structural changes in COVID-19 patients–an MRI-based 3-month follow-up study. EClinicalMedicine [Internet]. 2020;25. Available from: https://reader.elsevier.com/reader/sd/pii/S2589537020302285?token=4DE7496D93D03FF11F59CAB020D7C276A2099B694127BC364FCDE278C0EDED8F388F1DFEEC5BDE25AF907FD1762B04A6&originRegion=us-east-1&originCreation=20230309020343

31. Buonsenso D, Munblit D, De Rose C, Sinatti D, Ricchiuto A, Carfi A, et al. Preliminary evidence on Long Covid in children. Acta Paediatrica. 2021;110(7):2208–11.

32. Borch L, Holm M, Knudsen M, Ellermann-Eriksen S, Hagstroem S. Long covid symptoms and duration in SARS-COV-2 positive children — a nationwide cohort study. European Journal of Pediatrics. 2022;181(4):1597–607.

33. Lin Z, Long F, Yang Y, Chen X, Xu L, Yang M. Serum ferritin as an independent risk factor for severity in COVID-19 patients. Journal of Infection. 2020 Oct;81(4):647–79.

34. Vargas-Vargas M, Cortés-Rojo C. Ferritin levels and COVID-19. Revista Panamericana de Salud Pública. 2020 June 1;44:1.

35. Ashkenazi-Hoffnung L, Shmueli E, Ehrlich S, Ziv A, Bar-On O, Birk E, et al. Long Covid in children. Pediatric Infectious Disease Journal [Internet]. 2021;40(12). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575093/

36. Brackel C, Lap C, Buddingh E, van Houten M, van der Sande L, Langereis E, et al. Pediatric long□covid: An overlooked phenomenon? Pediatric Pulmonology. 2021;56(8):2495–502.

Table 1: Distribution of baseline clinical and demographic characteristics among Jamaican children being evaluated for Long COVID

Characteristics	Total Sample	Hospitalized (n=24, 32.4%)	Not hospitalized (n=50, 67.6%)	MIS-C present (n = 20, 27.0%)	MIS-C absent (n=54, 73.0%)	Long COVID present (n=35, 47.3%)	Long COVID absent (n=39, 52.7%)
Gender							
Male	40, 54.1%	13 (54.2%)	27 (54.0%)	11 (55.0%)	29 (53.7%)	16 (45.7%)	24 (61.5%)
Female	34, 45.9%	11 (45.8%)	23 (46.0%)	9 (45.0%)	25 (46.3%)	19 (54.3%)	15 (38.5%)
Variant							
Delta	30, 40.5%	8 (33.3%)	22 (44.0%)	10 (50.0%)	20 (37.0%)	17 (48.6%)	13 (33.3%)
Omicron	44, 59.5%	16 (66.7%)	28 (56.0%)	10 (50.0%)	34 (63.0%)	18 (51.4%)	26 (66.7%)
Age groups							
< 6 yrs	31, 41.9%	8 (33.3%)	23 (46.0%)	7 (35.0%)	24 (44.4%)	11 (31.4%)	20 (51.3%)
6-12 yrs	16, 21.6%	6 (25.0%)	10 (20.0%)	8 (40.0%)	8 (14.8%)	9 (25.7%)	7 (18.0%)
> 12 yrs	27, 36.5%	10 (41.7%)	17 (34.0%)	5 (25.0%)	22 (40.7%)	15 (42.9%)	12 (30.8%)
Diagnosis							
Lab confirmed	69, 94.5%	21 (91.3%)	48 (96.0%)	16 (84.2%)	53 (98.2%)	33 (97.5%)	36 (94.7%)
Physician confirmed	3, 4.1%	1 (4.4%)	2 (4.0%)	2 (10.5%)	1 (1.9%)	1 (2.6%)	1 (2.6%)
Self-diagnosed	1, 1.4%	1 (4.4%)	0 (0.0%)	1 (5.3%)	0 (0%)	1 (2.6%)	1 (2.6%)
Antigen positive	20, 34.5%	6 (28.6%)	14 (37.8%)	2 (13.3%)	18 (41.8%)	8 (28.6%)	12 (40.0%)
Antigen negative	38, 65.5%	15 (71.4%)	23 (62.2%)	13 (86.7%)	25 (58.1%)	20 (71.4%)	18 (60.0%)
PCR positive	44, 59.5%	13 (54.2%)	31 (62.0%)	0 (0.0%)	44 (81.5%)	19 (54.3%)	25 (64.1%)
PCR negative	30, 40.5%	11 (45.8%)	19 (38.0%)	20 (100.0%)	10 (18.5%)	16 (45.7%)	14 (35.9%)
Serology positive	21, 48.8%	6 (54.6%)	15 (46.9%)	16 (88.9%)	5 (20.0%)	12 (54.6%)	9 (42.9%)
Serology negative	22, 51.2%	5 (45.5%)	17 (53.1%)	2 (11.1%)	20 (80.0%)	10 (45.5%)	12 (57.1%)
Asthma							
Present	17 (23.0%)	4 (16.7%)	13 (26.0%)	5 (25.0%)	12 (22.2%)	9 (25.7%)	8 (20.5%)
Absent	57 (77.0%)	20 (83.3%)	37 (74.0%)	15 (75.0%)	42 (77.8%)	26 (74.3%)	31 (79.5%)
Obesity							
Present	9 (12.2%)	2 (8.3%)	7 (14.05)	3 (15.0%)	6 (11.1%)	4 (11.4%)	5 (12.8%)
Absent	65 (87.8%)	22 (91.7%)	43 (86.0%)	17 (85.0%)	48 (88.9%)	31 (88.6%)	34 (87.2%)
Neurological disorders							
Present	7 (9.5%)	3 (12.5%)	4 (8.05)	20 (100.0%)	7 (13.0%)	3 (8.6%)	4 (10.3%)
Absent	67 (90.5%)	21 (87.5%)	46 (92.0%)	0 (0.0%)	47 (87.0%)	32 (91.4%)	35 (89.7%)
History of Food Allergies							
Present	7 (9.5%)	2 (8.3%)	5 (10.0%)	2 (10.0%)	49 (90.7%)	3 (8.6%)	4 (10.3%)
Absent	67 (90.5%)	22 (91.7%)	45 (90.0%)	18 (90.0%)	5 (9.3%)	32 (91.4%)	35 (89.7%)
Sickle cell disease							
Present	17 (23.0%)	2 (8.3%)	5 (10.0%)	***5 (25.0%)**	***2 (3.7%)**	3 (8.6%)	4 (10.3%)
Absent	57 (77.0%)	22 (91.7%)	45 (90.0%)	***15 (75.0%)**	***52 (96.3%)**	32 (91.4%)	35 (89.7%)

† $p<0.05$: * and bold;



Figure 1: Prevalence of Acute and Chronic Symptoms based on Long-COVID Status

Table 2. Quality of life and functional impairment among Jamaican children being evaluated for Long COVID

Health parameter	Total (n=74)		Long COVID Present (n=35, 47.3%)		Long COVID Absent (n=39, 52.7%)		P-value
	Initial	Follow-up	Initial	Follow-up	Initial	Follow-up	
Mobility							
No problems	39, 97.5%	37, 92.5%	21, 95.5%	20, 90.9%	18, 100.0%	17, 94.4%	0.000
Some problems	0, 0.0%	1, 2.5%	0, 0.0%	1, 4.6%	0, 0.0%	0, 0.0%	
Many problems	1, 2.5%	2, 5.0%	1, 2.6%	1, 4.6%	0, 0.0%	1, 5.6%	
Self-care							
No problems	36, 90.0%	36, 90.0%	21, 95.5%	21, 95.5%	15, 83.3%	15, 83.3%	0.237
Some problems	1, 2.5%	2, 5.0%	0, 0.0%	0, 0.0%	1, 5.6%	2, 11.1%	
Many problems	3, 7.5%	2, 5.0%	1, 4.6%	1, 4.6%	2, 11.1%	1, 5.6%	
Usual activities							
No problems	37, 92.5%	35, 87.5%	20, 90.9%	19, 86.3%	17, 94.4%	16, 88.9%	0.155
Some problems	2, 5.0%	3, 7.5%	1, 4.6%	2, 9.1%	1, 5.6%	1, 5.6%	
Many problems	1, 2.5%	2, 5.0%	1, 4.6%	1, 4.6%	0, 0.0%	1, 5.6%	
Pain or discomfort							
No problems	28, 70.0%	24, 60.0%	14, 63.6%	12, 54.6%	14, 77.8%	12, 66.7%	0.997
Some problems	8, 20.0%	15, 37.5%	6, 27.3%	9, 40.9%	2, 11.1%	6, 33.3%	
Many problems	4, 10.0%	1, 2.5%	2, 9.1%	1, 4.6%	2, 11.1%	0, 0.0%	
Negative emotions							
No problems	25, 62.5%	20, 50.0%	15, 68.2%	11, 50.0%	10, 55.6%	9, 50.0%	0.631
Some problems	13, 32.5%	18, 45.0%	6, 27.3%	10, 45.5%	7, 38.9%	8, 44.4%	
Many problems	2, 5.0%	2, 5.0%	1, 4.6%	1, 4.6%	1, 5.6%	1, 5.6%	

Table 3. Inflammatory markers and Therapeutic Interventions among Jamaican children being evaluated for Long COVID

	Long COVID-19 Present (n=35, 47.3%)	**Long COVID-19 Absent (n=39, 52.7%)**
Inflammatory Markers	**Median (interquartile range)**	**Median (interquartile range)**
C-Reactive Protein	4.4 (0.6-5.5)	3.9 (0.5-4.4)
Erythrocyte Sedimentation Rate	98.5 (21-130)	29.5 (11-65)
D-dimer	2245 (497-4936)	1407 (247-2154)
Ferritin	***265.5 (143-1520)**	***337.5 (155-464)**
Lactate Dehydrogenase	485 (354-682)	440 (326-715)
Absolute Neutrophil Count	10.7 (3.3-65)	9.2 (2.8-23.9)
Interventions	**Frequency (%)**	**Frequency (%)**
Anti-inflammatory drugs Present Absent	 1, 2.9% 34, 97.1%	 1, 2.6% 38, 97.4%
Immunoglobulin Present Absent	6, 17.1% 29, 82.9%	4, 10.3% 35, 89.7%
Aspirin Present Absent	5, 14.3% 30, 85.7%	3, 7.7% 36, 92.3%
Antivirals Present Absent	1, 2.9% 34, 97.1%	2, 5.1% 37, 94.9%
Antibiotics Present Absent	13, 37.1% 22, 62.9%	18, 46.2% 21, 53.9%
Corticosteroids Present Absent	9, 25.7% 26, 74.3%	12, 30.8% 27, 69.2%

† p<0.05: * and bold; † Reference ranges: C-Reactive Protein: < 1.0 mg/dL; Erythrocyte Sedimentation Rate < 20 mm/hr; D-dimer < 500 ng/mL; Ferritin: 10-330 ng/mL; Lactate Dehydrogenase:105-200 U/L; Absolute Neutrophil Count:1.63-6.96

Table 4. Univariate and Multivariate Poisson Regression assessing incidence of Long COVID among Jamaican children

	Univariables				**Multivariables**			
Predictors	**Incidence Rate Ratio (IRR)**	**95% Confidence Interval**	**Robust Standard Error**	**P-value**	**Incidence Rate Ratio (IRR)**	**95% Confidence Interval**	**Robust Standard Error**	**P-value**
Age groups (ref. less than 6 years)								
6-12 years	1.6	0.8, 3.0	0.5	0.16	1.5	0.8, 2.8	0.5	0.24
12 years and older	1.6	0.9, 2.8	0.5	0.13	1.4	0.7, 2.6	0.4	0.35
Female (ref: Male)	1.4	0.9, 2.3	0.4	0.18	1.5	0.9, 2.6	0.4	0.13
Hospitalized (ref: not hospitalized)	0.5	0.3, 1.0	0.2	0.06	0.6	0.3, 1.1	0.2	0.08
Omicron (ref: Delta)	0.7	0.5, 1.2	0.2	0.18	0.8	0.5, 1.3	0.2	0.32
MIS-C present (ref: absent)	1.6	1.0, 2.5	0.4	0.046	1.8	1.0, 3.0	0.5	0.03
Confusion (ref: absent)	2.2	1.7, 2.8	0.3	<0.001				
Fatigue (ref: absent)	1.6	1.0, 2.6	0.4	0.042	1.2	0.7, 2.2	0.4	0.45
Vomiting (ref: absent)	2.0	1.3, 3.0	0.4	0.001	2.7	1.6, 4.4	0.7	<0.001
Abdominal pain (ref: absent)	2.2	1.7, 2.8	0.3	<0.001				
Loss of smell (ref: absent)	2.3	1.7, 2.9	0.3	<0.001	0.5	0.2, 1.2	0.2	0.14
Loss of taste (ref: absent)	2.3	1.8, 3.2	0.4	<0.001	3.2	1.7, 5.9	1.0	<0.001
Brain fog (ref: absent)	2.2	1.7, 2.8	0.3	<0.001				

† ‘ref:’ is an abbreviation for ‘reference:’

† Empty cells in the multivariate table represent independent variables that did not fit into the best fitting multivariate model